Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. A new study led by Memorial Sloan Kettering Cancer Center and published in Nature Cancer1 demonstrates that the Guardant360® liquid biopsy test effectively identified patients with PIK3CA mutations along with other mutations that correlate with treatment resistance. The phase I/II study (NCT01870505), a longitudinal analysis of tumor and blood-based circulating tumor DNA (ctDNA) in metastatic patients treated with alpelisib plus fulvestrant showed 89 percent concordance between tissue and blood for PIK3CA mutations. In the study, the Guardant360 liquid biopsy test also detected significantly more potential resistance alterations compared to tissue biopsy testing. These findings build upon the plasmaMATCH study results2 showing the importance of us
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health, Inc. (NASDAQ: GH) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
- Amplifier Security emerges from stealth to bridge divide between the workforce and security with AI copilot and human-in-the-loop automation [Yahoo! Finance]Yahoo! Finance
- Putting The Human Touch Back Into Cybersecurity With Amplifier [Forbes]Forbes
- FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 [Yahoo! Finance]Yahoo! Finance
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23Business Wire
GH
Earnings
- 2/22/24 - Beat
GH
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- GH's page on the SEC website